Martínez-Baños Déborah, Sánchez-Hernández Beatríz, Jiménez Guadalupe, Barrera-Lumbreras Georgina, Barrales-Benítez Olga
Department of Hematology and Oncology, National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Tlalpan 14080, Mexico.
Department of Genetics, National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Tlalpan 14080, Mexico.
Exp Ther Med. 2017 May;13(5):2442-2450. doi: 10.3892/etm.2017.4274. Epub 2017 Mar 28.
Tumor suppressor gene promoter CpG island methylation is a well-recognized mechanism in cancer pathogenesis, but its role in multiple myeloma (MM) is controversial. The present study investigated the methylation status and expression of , suppressor of cytokine signaling 1 (), and Src homology region 2 domain-containing phosphatase 1 (), as well as global methylation in patients with MM during active disease and remission. Bone marrow samples were obtained from 43 patients at the Multiple Myeloma Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico City, Mexico) during active disease and remission. Methylation-specific polymerase chain reaction and ELISA were performed on bisulfite-treated or untreated DNA to determine promoter-specific or genomic methylation, respectively. Gene expression was measured using reverse-transcription polymerase chain reaction. The results indicated that methylation occurred more frequently during active disease than remission [29 vs. 3.2% (P=0.021)] and was associated with more advanced forms of the disease [international staging system (ISS) 3, 16.67% vs. ISS 1, 8.3% (P=0.037)]. methylation during active disease was associated with a lower probability of survival at 39-month follow up (median), 52.5 vs. 87.5% (P=0.025). The percentage of methylation was associated with active disease at remission, but this was not significant. Global hypomethylation at remission was a negative predictor factor for overall survival (OS). The results indicated that methylated , and were associated with clinical variables of poor prognosis in MM, likewise the persistence of global hypomethylation at remission. The negative impact on OS of global hypomethylation at remission must be confirmed in a larger sample. Future studies are necessary to investigate whether patients with global hypermethylation at remission should receive more aggressive treatments to improve their OS.
肿瘤抑制基因启动子CpG岛甲基化是癌症发病机制中一种广为人知的机制,但其在多发性骨髓瘤(MM)中的作用存在争议。本研究调查了细胞因子信号传导抑制因子1(SOCS1)、含Src同源区2结构域的磷酸酶1(SHP1)的甲基化状态和表达,以及MM患者在疾病活动期和缓解期的整体甲基化情况。从墨西哥城墨西哥国立医学与营养科学研究所萨尔瓦多·苏比拉án多发性骨髓瘤诊所的43例患者中获取骨髓样本,分别在疾病活动期和缓解期进行检测。对经亚硫酸氢盐处理或未处理的DNA分别进行甲基化特异性聚合酶链反应和酶联免疫吸附测定,以确定启动子特异性或基因组甲基化。使用逆转录聚合酶链反应测量基因表达。结果表明,SOCS1甲基化在疾病活动期比缓解期更频繁发生[29%对3.2%(P = 0.021)],并且与疾病的更晚期形式相关[国际分期系统(ISS)3期,16.67%对ISS 1期,8.3%(P = 0.037)]。疾病活动期的SHP1甲基化与39个月随访(中位数)时较低的生存概率相关,52.5%对87.5%(P = 0.025)。甲基化百分比与缓解期的疾病活动相关,但不显著。缓解期的整体低甲基化是总生存期(OS)的负预测因素。结果表明,甲基化的SOCS1、SHP1与MM预后不良的临床变量相关,缓解期整体低甲基化的持续存在情况同样如此。缓解期整体低甲基化对OS的负面影响必须在更大样本中得到证实。未来有必要开展研究调查缓解期整体高甲基化的患者是否应接受更积极的治疗以改善其OS。